Strainprint Technologies Launches
Revolutionary New Mobile App For Cannabis Patients
TORONTO - April 5, 2017 (Investorideas.com Newswire) StrainprintTM Technologies
Ltd. ("StrainprintTM")
-- a leader in cannabis patient data collection -- is proud to announce the
commercial launch of a revolutionary Cannabis Tracking APP & platform. The
mobile APP is free for patients and is available for both Apple iOS &
Android.
StrainprintTM enables cannabis patients to track and
understand the efficacy of their cannabis use by strain, quantity, method of
ingestion and dose. Using standardized pain scales, this much-needed data will
help patients use cannabis more effectively and help clinicians to better
tailor therapeutic regimens. Strainprint's database contains all strains and
products available under the Access to Cannabis for Medical Purposes
Regulations program (ACMPR). Patients can also add their own unique/personal
strains.
"StrainprintTM will help patients and medical
practitioners to better understand how specific cannabis genetics and ingestion
methods provide the best therapy for over 170 applicable medical
conditions," said Alexander Repetski, Chief Communications Officer. "By
using individuals' data to fine-tune their treatment, StrainprintTM will
assist in improving the quality of life for those using cannabis. This data is
also needed by the academic community to accelerate research efforts and to
further enhance the understanding of cannabis," he added.
The HIPAA and PIPEDA compliant solution is already identifying
valuable and fascinating efficacy trends across a variety of medical
conditions. This information will enable patients, producers, clinicians and
other supply chain partners to better understand the needs of patients and how
specific cannabinoids effect a multitude of conditions.
"The importance of this real-time crowd-sourced data is
integral to both governmental bodies and the academic community to accelerate
research efforts and further enhance the understanding of cannabis," said
StrainprintTM President, David
Berg. "With the pending legalization of recreational cannabis in Canada,
the data acquired by Strainprint also holds significance in determining many
facets of regulations concerning public health and safety," he added.
"StrainprintTM was created out of necessity. As a patient
who had limited knowledge about cannabis, the need for a tool to help guide and
enhance treatment seemed almost essential. It didn't exist, and that's why we
spent several years developing it. We're continually improving the software to
ensure a simple and rewarding experience," said Stephanie Karasick,
Founder & Chief Strategy Officer.
A new version of the APP will be released in the coming weeks
with an exciting Loyalty Program, where users can redeem accumulated points for
cannabis-related products and merchandise.
Learn more about Strainprint at: www.strainprint.ca
Connect with Strainprint on Facebook: www.facebook.com/strainprint
Follow us on Twitter: twitter.com/strainprint
Tweet: Strainprint Launches revolutionary mobile app for
cannabis patients. #strainprint
About
StrainprintTM:
Founded in 2016, StrainprintTM Technologies Ltd. is a Toronto-based
company providing enterprise grade analytics and consumer solutions for the
medical cannabis industry. StrainprintTM manages the gathering and analysis of
real-time cannabis consumption data and ranks specific strain efficacy against
conditions and related symptoms. Analyzing anonymous patient treatment
data and efficacy measures will help to identify new treatment protocols for
the medical community and patients. StrainprintTM also works with commercial producers
and clinics to provide advanced intelligence to optimize grow operations and
treatment methods.
Media
Contact:
Alexander E. Repetski, CCO
Strainprint Technologies Ltd.
647.282.3825
Watch the 420
Cannabis Investor video
More Info:
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
No comments:
Post a Comment